Abstract
Tuberculosis (TB) remains a significant cause of death worldwide, and emergence of drug-resistant TB requires lengthy treatments with toxic drugs that are less effective than their first-line equivalents. New treatments are urgently needed. Delamanid, previously OPC-67863, is a novel drug of the dihydro-nitroimidazole class with potent anti-TB activity and great promise to be effective in the treatment of drug-resistant TB. This review examines the preclinical and clinical development of delamanid, reviews current guidance on its use and evaluates the opportunities and challenges for its future role in TB management.
| Original language | English |
|---|---|
| Pages (from-to) | 779-791 |
| Number of pages | 13 |
| Journal | Therapeutics and Clinical Risk Management |
| Volume | 11 |
| DOIs | |
| Publication status | Published - 13 May 2015 |
Keywords
- Delamanid
- OPC-67683
- Tuberculosis
- Drug resistance
- MDR-TB
Access to Document
- Sloan_2015_Delamanid_T&CRM_CC
© 2015 Lewis and Sloan. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.